Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2020-05-12 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated May 12, 2020, announcing that Glenmark Pharmaceuticals has initiated Phase 3 clinical trials on the antiviral Favipiravir for COVID-19 patients in India. It is addressed to stock exchanges and includes a media release for immediate distribution. The content focuses on the clinical trial initiation, study details, and company statements, without any financial data, regulatory filings, or report attachments. It is not an annual or interim report, earnings release, or any other financial or regulatory filing. The document is a corporate announcement about a clinical trial initiation, which fits best under the category of a general regulatory announcement or miscellaneous filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-05-12 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product (a 3-in-1 inhaler therapy for COPD) by Glenmark Pharmaceuticals. It is addressed to stock exchanges and includes a media release with product details, benefits, and references. There are no financial statements, regulatory certifications, voting results, or management discussions. The content is promotional and informational about a product launch rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories, which is Regulatory Filings (RNS). The document length is 7403 characters, which is not extremely short, but the content clearly is a press release rather than a report publication announcement or financial report.
2020-05-11 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received regulatory approval from the Drug Controller General of India (DCGI) to conduct clinical trials on Favipiravir antiviral tablets for COVID-19 patients. It is addressed to stock exchanges and includes a media release. The content is an announcement of a regulatory approval and clinical trial initiation, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content. The document length is about 4854 characters, which is relatively short and consistent with a press release or regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received tentative approval from the U.S. FDA for a specific drug product. It is addressed to stock exchanges and is a formal notification of a regulatory milestone. The content is a corporate announcement about a product approval, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is 3603 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-04-29 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated March 23, 2020, announcing Glenmark Pharmaceuticals' divestment of its VWash brand to Hindustan Unilever. It contains no financial statements, no detailed financial data, no regulatory form references, or voting results. The content is a corporate announcement about a business transaction (divestment) rather than a merger or acquisition filing, and it is not a full financial report or earnings release. It is also not a regulatory filing or certification. The document is a straightforward announcement of a capital transaction (divestment of a brand), which fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters but it is not merely announcing the publication of a report; it is the announcement itself. Therefore, the appropriate classification is CAP with high confidence.
2020-03-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated March 23, 2020, announcing that Glenmark Pharmaceuticals has received tentative approval from the U.S. FDA for a specific drug (Dapagliflozin Tablets). It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a regulatory announcement about product approval and does not contain financial data, earnings, management discussion, or any detailed report. It is not a financial report, earnings release, or management report. It is also not a voting result, board change, or capital update. The document is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2020-03-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.